LASA SUPERGENERICS
|
LASA SUPERGENERICS Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -4.34 | -7.71 | -1.06 | 5.60 | 0.89 |
| CEPS(Rs) | -2.21 | -5.03 | 1.83 | 9.49 | 5.16 |
| DPS(Rs) | - | - | 0.25 | 0.25 | - |
| Book NAV/Share(Rs) | 19.30 | 23.61 | 31.51 | 39.07 | 34.78 |
| Tax Rate(%) | -13.70 | 8.62 | 13.16 | 22.76 | 23.39 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 2.13 | -5.09 | 11.68 | 23.33 | 17.91 |
| EBIT Margin(%) | -16.41 | -29.39 | -4.43 | 15.59 | 7.69 |
| Pre Tax Margin(%) | -18.32 | -32.62 | -4.48 | 14.57 | 2.83 |
| PAT Margin (%) | -20.83 | -29.81 | -3.89 | 11.25 | 2.17 |
| Cash Profit Margin (%) | -10.60 | -19.45 | 6.69 | 19.07 | 12.53 |
| Performance Ratios | |||||
| ROA(%) | -13.81 | -20.71 | -2.56 | 10.43 | 1.50 |
| ROE(%) | -20.22 | -27.97 | -3.37 | 15.17 | 2.94 |
| ROCE(%) | -13.23 | -23.94 | -3.41 | 17.14 | 6.77 |
| Asset Turnover(x) | 0.66 | 0.69 | 0.66 | 0.93 | 0.69 |
| Sales/Fixed Asset(x) | 0.45 | 0.56 | 0.60 | 0.91 | 0.78 |
| Working Capital/Sales(x) | -9.50 | -36.94 | 6.36 | 8.51 | -3,684.39 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 2.20 | 1.78 | 1.68 | 1.10 | 1.29 |
| Receivable days | 10.61 | 29.63 | 44.35 | 31.94 | 54.04 |
| Inventory Days | 57.63 | 35.78 | 38.27 | 39.28 | 63.18 |
| Payable days | 56.97 | 45.30 | 59.24 | 75.46 | 180.10 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | 10.70 | 31.83 |
| PCE(x) | -9.95 | -3.67 | 22.76 | 6.31 | 5.51 |
| Price/Book(x) | 1.14 | 0.78 | 1.32 | 1.53 | 0.82 |
| Yield(%) | - | - | 0.60 | 0.42 | - |
| EV/Net Sales(x) | 1.25 | 0.86 | 1.55 | 1.28 | 0.94 |
| EV/Core EBITDA(x) | 56.20 | -23.51 | 13.00 | 5.46 | 5.23 |
| EV/EBIT(x) | -7.63 | -2.94 | -34.88 | 8.20 | 12.28 |
| EV/CE(x) | 1.10 | 0.80 | 1.01 | 1.24 | 0.83 |
| M Cap / Sales | 1.05 | 0.71 | 1.52 | 1.20 | 0.69 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -19.47 | -5.51 | -32.24 | 21.00 | -1.37 |
| Core EBITDA Growth(%) | 148.85 | -129.21 | -65.60 | 56.89 | 160.58 |
| EBIT Growth(%) | 55.03 | -526.82 | -119.25 | 145.38 | 266.60 |
| PAT Growth(%) | 43.73 | -624.41 | -123.41 | 527.76 | 130.16 |
| EPS Growth(%) | 43.73 | -624.41 | -119.00 | 527.76 | 116.95 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.23 | 0.18 | 0.13 | 0.12 | 0.34 |
| Current Ratio(x) | 0.78 | 0.92 | 1.48 | 1.59 | 1.00 |
| Quick Ratio(x) | 0.39 | 0.59 | 1.22 | 1.16 | 0.65 |
| Interest Cover(x) | -8.60 | -9.09 | -93.74 | 15.28 | 1.58 |
| Total Debt/Mcap(x) | 0.20 | 0.24 | 0.12 | 0.08 | 0.42 |
Compare Financial Ratios of peers of LASA SUPERGENERICS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LASA SUPERGENERICS | ₹131.6 Cr | 6.4% | -4.3% | -15.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹431,400.0 Cr | 0.3% | -2.6% | 36.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹154,622.0 Cr | -1% | -0.5% | 60.8% | Stock Analytics | |
| CIPLA | ₹116,240.0 Cr | -1.4% | -3.1% | 11.8% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹108,166.0 Cr | -3.8% | -4% | 15.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,495.2 Cr | 0.1% | 1.2% | 40.3% | Stock Analytics | |
LASA SUPERGENERICS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LASA SUPERGENERICS | 6.4% |
-4.3% |
-15.8% |
| SENSEX | -0.4% |
-2.1% |
6.9% |
You may also like the below Video Courses
